Literature DB >> 31620224

Peptide-Cleavable Self-immolative Maytansinoid Antibody-Drug Conjugates Designed To Provide Improved Bystander Killing.

Juliet A Costoplus1, Karen H Veale1, Qifeng Qiu1, Jose F Ponte1, Leanne Lanieri1, Yulius Setiady1, Ling Dong1, Anna Skaletskaya1, Laura M Bartle1, Paulin Salomon1, Rui Wu1, Erin K Maloney1, Yelena V Kovtun1, Olga Ab1, Kate Lai1, Ravi V J Chari1, Wayne C Widdison1.   

Abstract

A new type of antibody-drug conjugate (ADC) has been prepared that contains a sulfur-bearing maytansinoid attached to an antibody via a highly stable tripeptide linker. Once internalized by cells, proteases in catabolic vesicles cleave the peptide of the ADC's linker causing self-immolation that releases a thiol-bearing metabolite, which is then S-methylated. Conjugates were prepared with peptide linkers containing only alanyl residues, which were all l isomers or had a single d residue in one of the three positions. A d-alanyl residue in the linker did not significantly impair a conjugate's cytotoxicity or bystander killing unless it was directly attached to the immolative moiety. Increasing the number of methylene units in the maytansinoid side chain of a conjugate did not typically affect an ADC's cytotoxicity to targeted cells but did increase bystander killing activity. ADCs with the highest in vitro bystander killing were then evaluated in vivo in mice, where they displayed improved efficacy compared to previously described types of maytansinoid conjugates.
Copyright © 2019 American Chemical Society.

Entities:  

Year:  2019        PMID: 31620224      PMCID: PMC6792174          DOI: 10.1021/acsmedchemlett.9b00310

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  23 in total

Review 1.  An emerging playbook for antibody-drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety.

Authors:  Penelope M Drake; David Rabuka
Journal:  Curr Opin Chem Biol       Date:  2015-09-02       Impact factor: 8.822

2.  IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.

Authors:  Olga Ab; Kathleen R Whiteman; Laura M Bartle; Xiuxia Sun; Rajeeva Singh; Daniel Tavares; Alyssa LaBelle; Gillian Payne; Robert J Lutz; Jan Pinkas; Victor S Goldmacher; Thomas Chittenden; John M Lambert
Journal:  Mol Cancer Ther       Date:  2015-04-22       Impact factor: 6.261

3.  Novel peptide linkers for highly potent antibody-auristatin conjugate.

Authors:  Svetlana O Doronina; Tim D Bovee; David W Meyer; Jamie B Miyamoto; Martha E Anderson; Carol A Morris-Tilden; Peter D Senter
Journal:  Bioconjug Chem       Date:  2008-09-20       Impact factor: 4.774

Review 4.  Cleavable linkers in antibody-drug conjugates.

Authors:  Jonathan D Bargh; Albert Isidro-Llobet; Jeremy S Parker; David R Spring
Journal:  Chem Soc Rev       Date:  2019-08-12       Impact factor: 54.564

5.  Predicting a Drug's Membrane Permeability: A Computational Model Validated With in Vitro Permeability Assay Data.

Authors:  Brian J Bennion; Nicholas A Be; M Windy McNerney; Victoria Lao; Emma M Carlson; Carlos A Valdez; Michael A Malfatti; Heather A Enright; Tuan H Nguyen; Felice C Lightstone; Timothy S Carpenter
Journal:  J Phys Chem B       Date:  2017-05-12       Impact factor: 2.991

6.  Semisynthetic maytansine analogues for the targeted treatment of cancer.

Authors:  Wayne C Widdison; Sharon D Wilhelm; Emily E Cavanagh; Kathleen R Whiteman; Barbara A Leece; Yelena Kovtun; Victor S Goldmacher; Hongsheng Xie; Rita M Steeves; Robert J Lutz; Robert Zhao; Lintao Wang; Walter A Blättler; Ravi V J Chari
Journal:  J Med Chem       Date:  2006-07-13       Impact factor: 7.446

7.  Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.

Authors:  Jose F Ponte; Xiuxia Sun; Nicholas C Yoder; Nathan Fishkin; Rassol Laleau; Jennifer Coccia; Leanne Lanieri; Megan Bogalhas; Lintao Wang; Sharon Wilhelm; Wayne Widdison; Jan Pinkas; Thomas A Keating; Ravi Chari; Hans K Erickson; John M Lambert
Journal:  Bioconjug Chem       Date:  2016-06-20       Impact factor: 4.774

8.  Selective cleavage of welan gum (S-130) by oxidative decarboxylation with lead tetraacetate.

Authors:  N S Kumar; R M Ratnayake; G Widmalm; P E Jansson
Journal:  Carbohydr Res       Date:  1996-09-23       Impact factor: 2.104

9.  Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.

Authors:  Yelena V Kovtun; Charlene A Audette; Yumei Ye; Hongsheng Xie; Mary F Ruberti; Sara J Phinney; Barbara A Leece; Thomas Chittenden; Walter A Blättler; Victor S Goldmacher
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

10.  Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice.

Authors:  Hongsheng Xie; Charlene Audette; Mary Hoffee; John M Lambert; Walter A Blättler
Journal:  J Pharmacol Exp Ther       Date:  2003-11-21       Impact factor: 4.030

View more
  7 in total

1.  New Chemical Modalities and Strategic Thinking in Early Drug Discovery.

Authors:  Maria-Jesus Blanco; Kevin M Gardinier
Journal:  ACS Med Chem Lett       Date:  2020-01-14       Impact factor: 4.345

Review 2.  Antibody-Drug Conjugates in Uro-Oncology.

Authors:  Dawid Sigorski; Paweł Różanowski; Ewa Iżycka-Świeszewska; Katarzyna Wiktorska
Journal:  Target Oncol       Date:  2022-05-14       Impact factor: 4.864

3.  Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders.

Authors:  Paola Marzullo; Zlata Boiarska; Helena Pérez-Peña; Anne-Catherine Abel; Beatriz Álvarez-Bernad; Daniel Lucena-Agell; Francesca Vasile; Maurizio Sironi; Karl-Heinz Altmann; Andrea E Prota; J Fernando Díaz; Stefano Pieraccini; Daniele Passarella
Journal:  Chemistry       Date:  2021-11-29       Impact factor: 5.020

4.  Site-specific conjugation of native antibody.

Authors:  Amissi Sadiki; Shefali R Vaidya; Mina Abdollahi; Gunjan Bhardwaj; Michael E Dolan; Harpreet Turna; Varnika Arora; Athul Sanjeev; Timothy D Robinson; Andrea Koid; Aashka Amin; Zhaohui Sunny Zhou
Journal:  Antib Ther       Date:  2020-12-18

5.  Synthesis and Evaluation of Small Molecule Drug Conjugates Harnessing Thioester-Linked Maytansinoids.

Authors:  Chen-Fu Lo; Tai-Yu Chiu; Yu-Tzu Liu; Li-Rung Huang; Teng-Kuang Yeh; Kuan-Hsun Huang; Kuan-Liang Liu; Chia-Yu Hsu; Ming-Yu Fang; Yu-Chen Huang; Tsu-An Hsu; Chiung-Tong Chen; Lun Kelvin Tsou
Journal:  Pharmaceutics       Date:  2022-06-21       Impact factor: 6.525

6.  Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates.

Authors:  Tomohiro Fujii; Calliste Reiling; Colette Quinn; Michal Kliman; Brian A Mendelsohn; Yutaka Matsuda
Journal:  Explor Target Antitumor Ther       Date:  2021-12-31

Review 7.  The Chemistry Behind ADCs.

Authors:  Vesela Kostova; Patrice Désos; Jérôme-Benoît Starck; Andras Kotschy
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.